686766-52-9 Usage
Explanation
The full name of the compound, which describes its structure and composition.
Explanation
The compound is derived from 1,2-pyrrolidinedicarboxylic acid by forming an ester linkage.
Explanation
The parent compound from which the ester derivative is formed.
Explanation
The ester group attached to the parent compound, which is derived from 1,1-dimethylethyl alcohol.
Explanation
A 2-fluorophenoxy group is attached to the ester moiety, which may impart specific chemical and biological properties to the molecule.
Explanation
The stereochemistry of the compound, indicating the spatial arrangement of the substituents around the chiral centers.
Explanation
The compound is commonly used as a precursor in the synthesis of pharmaceuticals and agrochemicals due to its unique structure and properties.
Explanation
The compound's specific properties and stereochemistry make it a promising candidate for further research and development in the field of medicinal chemistry and drug development.
Type of Compound
Ester derivative
Parent Compound
1,2-Pyrrolidinedicarboxylic acid
Ester Moiety
1-(1,1-dimethylethyl) ester
Substituent
4-(2-fluorophenoxy) group
Stereochemistry
(2S,4S)-
Applications
Pharmaceutical and agrochemical synthesis
Potential Applications
Medicinal chemistry and drug development
Check Digit Verification of cas no
The CAS Registry Mumber 686766-52-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,6,7,6 and 6 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 686766-52:
(8*6)+(7*8)+(6*6)+(5*7)+(4*6)+(3*6)+(2*5)+(1*2)=229
229 % 10 = 9
So 686766-52-9 is a valid CAS Registry Number.
686766-52-9Relevant articles and documents
NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES
-
Page/Page column 68, (2008/06/13)
The present invention relates to compounds with the formulas (I), (II), and (III), or a pharmaceutically acceptable salt thereof: wherein T is a (4 to 10)-membered heterocyclyl selected from the group consisting of and wherein R1. R2 and R3 are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formulas (I), (II), and (III) and methods of treating a condition that is mediated by the modulation of the 11-β-hsd-1 enzyme, the method comprising administering to a mammal an effective amount of a compound of formulas (I), (II), and (III).
